Compass Therapeutics (CMPX) Assets (2018 - 2026)

Compass Therapeutics' Assets history runs 9 years deep, the most recent figure standing at $205.2 million for Q1 2026.

• In Q1 2026, Assets rose 56.08% year-over-year to $205.2 million; the TTM figure through Mar 2026 stood at $205.2 million (up 56.08% YoY), while the FY2025 annual figure was $219.6 million, up 56.4% from the prior year.
• Assets came in at $205.2 million for Q1 2026 at Compass Therapeutics, down from $219.6 million in the prior quarter.
• In the past five years, Assets ranged from a high of $231.3 million in Q3 2025 to a low of $116.7 million in Q2 2025.
• A 5-year average of $165.8 million and a median of $156.9 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets jumped 266.31% in 2022 and retreated 25.01% in 2025, its largest moves.
• Compass Therapeutics' Assets stood at $199.6 million in 2022, then decreased by 21.42% to $156.9 million in 2023, then retreated by 10.5% to $140.4 million in 2024, then jumped by 56.4% to $219.6 million in 2025, then declined by 6.57% to $205.2 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $205.2 million, $219.6 million, and $231.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison